EXCELLENT EFFICACY AND SAFETY OF SOFOSBUVIR, GLECAPREVIR, PIBRENTASVIR AND RIBAVIRIN FOR RETREATMENT OF CHRONIC HEPATITIS C AFTER SOFOSBUVIR, VELPATASVIR AND VOXILAPREVIR FAILURE

被引：0
|
作者：
Saxena, Varun [1 ,2 ]
McKinney, Jeff [2 ]
Chamberland, Scott [1 ]
Catalli, Lisa [2 ]
Seo, Suk [1 ]
Ready, Joanna B. [3 ]
Price, Jennifer C. [2 ]
机构：
[1] Kaiser Permanente Northern Calif, Oakland, CA USA
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
[3] Kaiser Permanente Santa Clara Med Ctr, Santa Clara, CA USA
来源：
HEPATOLOGY | 2021年 / 74卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
98
引用
收藏
页码：66A / 67A
页数：2
相关论文
共 50 条
  • [21] Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy
    Dietz, Julia
    Di Maio, Velia Chiara
    de Salazar, Adolfo
    Merino, Dolores
    Vermehren, Johannes
    Paolucci, Stefania
    Kremer, Andreas E.
    Lara, Magdalena
    Pardo, Maria Rodriguez
    Zoller, Heinz
    Degasperi, Elisabetta
    Peiffer, Kai-Henrik
    Sighinolfi, Laura
    Tellez, Francisco
    Graf, Christiana
    Ghisetti, Valeria
    Schreiber, Jonas
    Fernandez-Fuertes, Elisa
    Boglione, Lucio
    Munoz-Medina, Leopoldo
    Stauber, Rudolf
    Gennari, William
    Figueruela, Blanca
    Santos, Jesus
    Lampertico, Pietro
    Zeuzem, Stefan
    Ceccherini-Silberstein, Francesca
    Garcia, Federico
    Sarrazin, Christoph
    JOURNAL OF HEPATOLOGY, 2021, 74 (04) : 801 - 810
  • [22] Sofosbuvir, velpatasvir and voxilaprevir combination for the treatment of hepatitis C
    Voaklander, Rebecca
    Jacobson, Ira M.
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2017, 11 (09) : 789 - 795
  • [23] Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C
    Childs-Kean, Lindsey M.
    Brumwell, Natalie A.
    Lodl, Emma F.
    INFECTION AND DRUG RESISTANCE, 2019, 12 : 2259 - 2268
  • [24] EFFICACY OF SOFOSBUVIR/ VELPATASVIR/ VOXILAPREVIR IN NAIVE CHRONIC HEPATITIS C PATIENTS: REAL LIFE STUDY
    Guner, Hatice Rahmet
    Yamazhan, Tansu
    Karabay, Oguz
    Inci, Ayse
    Yilmaz, Gurdal
    Aydin, Ozlem Altuntas
    Caglar, Yesim
    Senel, Ilknur
    Yildirim, Arzu Altuncekic
    Zerdali, Esra Yerlikaya
    Tatar, Bengu Gireniz
    Tabak, Fehmi
    HEPATOLOGY, 2023, 78 : S719 - S719
  • [25] Clinical and virological characteristics of patients with chronic hepatitis C and failure to voxilaprevir/velpatasvir/sofosbuvir treatment
    Dietz, Julia
    de Salazar, Adolfo
    Vermehren, Johannes
    Merino, Dolores
    zur Wiesch, Julian Schulze
    Lara, Magdalena
    Rodriguez Pardo, Maria Josefa
    Di Maio, Velia Chiara
    Paolucci, Stefania
    Degasperi, Elisabetta
    Zoller, Heinz
    Arenas Ruiz-Tapiador, Juan Ignacio
    Stauber, Rudolf E.
    Figueruela, Blanca
    Buti, Maria
    Lampertico, Pietro
    Zeuzem, Stefan
    Silberstein, Francesca Ceccherini
    Garcia Garcia, Federico
    Sarrazin, Christoph
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E219 - E220
  • [26] Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs
    Llaneras, Jordi
    Riveiro-Barciela, Mar
    Lens, Sabela
    Diago, Moises
    Cachero, Alba
    Garcia-Samaniego, Javier
    Conde, Isabel
    Arencibia, Ana
    Arenas, Juan
    Gea, Francisco
    Torras, Xavier
    Luis Calleja, Jose
    Antonio Carrion, Jose
    Fernandez, Inmaculada
    Maria Morillas, Rosa
    Miguel Rosales, Jose
    Carmona, Isabel
    Fernandez-Rodriguez, Conrado
    Hernandez-Guerra, Manuel
    Llerena, Susana
    Bernal, Vanesa
    Turnes, Juan
    Gonzalez-Santiago, Jesus M.
    Montoliu, Silvia
    Figueruela, Blanca
    Badia, Ester
    Delgado, Manuel
    Fernandez-Bermejo, Miguel
    Inarrairaegui, Mercedes
    Manuel Pascasio, Juan
    Esteban, Rafael
    Marino, Zoe
    Buti, Maria
    JOURNAL OF HEPATOLOGY, 2019, 71 (04) : 666 - 672
  • [27] SOFOSBUVIR/VELPATASVIR VS GLECAPREVIR/PIBRENTASVIR IN GENOTYPE 3 HEPATITIS C VIRUS INFECTED PATIENTS
    Margusino-Framinan, L.
    Cid-Silva, P.
    Rotea-Salvo, S.
    Mena-de-Cea, A.
    Delgado, M.
    Vazquez-Rodriguez, P.
    Sanclaudio-Luhia, I
    Suarez-Lopez, F.
    Herranz, I
    Castro-Iglesias, A.
    VALUE IN HEALTH, 2019, 22 : S640 - S640
  • [28] Real world outcomes from NS5a treatment failures undergoing therapy with sofosbuvir/velpatasvir/voxilaprevir and sofosbuvir/glecaprevir/pibrentasvir
    Boyle, Alison
    Marra, Fiona
    Fox, Raymod
    Gunson, Rory
    Bradley, Amanda
    Thomson, Emma
    Peters, Erica
    Barclay, Stephen
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E212 - E212
  • [29] Sofosbuvir/velpatasvir/voxilaprevir: a highly effective option for retreatment of hepatitis C in difficult-to-treat patients
    Mathur, Poonam
    Kottilil, Shyamasundaran
    Wilson, Eleanor
    ANTIVIRAL THERAPY, 2019, 24 (01) : 1 - 10
  • [30] Non-responders to sofosbuvir/velpatasvir/voxilaprevir in the treatment of chronic hepatitis C infection
    Karimi-Sari, Hamidreza
    Rezaee-Zavareh, Mohammad Saeid
    Falade-Nwulia, Oluwaseun
    Lim, Joseph K.
    JOURNAL OF HEPATOLOGY, 2022, 77 (04) : 1215 - 1217
12345